Mode
Text Size
Log in / Sign up
N/A N=100

Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues

Parkinson's Disease

Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcome: Primary: Visual Sampling Parameter: Saccade Frequency During Gait — 0.48; 0.76; 0.67; 0.77 Saccade frequency (sacc/sec)

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Newcastle-upon-Tyne Hospitals NHS Trust
Primary completion
Feb 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Visual Sampling Parameter: Saccade Frequency During Gait
0.48; 0.76; 0.67; 0.77; 1.05; 1.31
SECONDARY
Gait Parameter: Gait Speed
SECONDARY
Gait Parameter: Step Length
SECONDARY
Gait Parameter: Step Time
SECONDARY
Gait Parameter: Single Support Time
SECONDARY
Gait Parameter: Double Support Time
SECONDARY
Visual Sampling Parameter: Saccade Number During Gait
SECONDARY
Visual Sampling Parameter: Saccade Velocity During Gait
SECONDARY
Visual Sampling Parameter: Saccade Amplitude During Gait
SECONDARY
Visual Sampling Parameter: Saccade Acceleration During Gait
SECONDARY
Visual Sampling Parameter: Fixation Number During Gait
SECONDARY
Visual Sampling Parameter: Fixation Duration During Gait
SECONDARY
Visual Sampling Parameter: Saccade Duration During Gait
SECONDARY
Visual Sampling Parameter: Number of Blinks During Gait

Summary

Parkinson's disease (PD) is associated with problems of gait such as veering, difficulty turning, an inability to perceive doorways or obstacles, and negotiate uneven terrain. Gait problems, especially veering, may be exacerbated by visuospatial dysfunction which predispose to falls, freezing and festination of gait. Visuospatial dysfunction is common in PD and likely involves peripheral features (e.g. contrast sensitivity) as well as central cognitive mechanisms (e.g. attention). Central neuro-degeneration in PD, PD dementia, and dementia with Lewy Bodies may influence visual function, as impaired visual sampling has been reported in these conditions. Visual sampling is measured via saccadic (fast eye movement) activity, as saccades are the mechanisms through which people orientate and explore the environment. The use of objective devices to reliably measure saccades is important to detect disease related eye movement changes. Emerging visuomotor research has measured visual sampling in PD using devices such as electrooculography and infra-red eye tracking, revealing reduced amplitude, speed and frequency of saccades during various tasks. Despite recent increases in visuomotor research it remains unclear how PD influences visual sampling of the environment during gait and the influence of attentional and cognitive deficits. Recent work demonstrated that people with PD sample their environment less frequently than controls, despite a slower gait. Saccadic timing was unchanged in response to environmental cues. Despite this, environmental visual cues (transverse lines on the floor) have been shown to increase the number of fixations made during gait. However the mechanisms of this response remain unclear. Cognition is likely of importance, with response potentially influenced by attentional control. This observational study aims to examine the influence of cognition on visuomotor control during gait in PD. This aim will be achieved by observation of visual sampling under several environmental challenges (straight walk, doorways, turns, visual cue) and a dual task.

Eligibility Criteria

Inclusion Criteria

Common to all groups

  • Aged ≥50 years
  • Able to walk unaided
  • Adequate hearing (as evaluated by the whisper test; stand 2m behind participant and whisper a 2 syllable word, participant repeats word) and vision capabilities (as measured using a Snellen chart - 6/18-6/12).
  • Stable medication for the past 1 month and anticipated over a period of 6 months

Group Specific Criteria

Participants with PD:

  • Diagnosis of idiopathic PD, as defined by the UK Brain Bank criteria
  • Hoehn and Yahr stage I-III
  • Stable medication for past 1 month and anticipated over next 6 months or stable Deep Brain Stimulation for at least one month and expected following 6 months
  • Score ≥21/30 on Montreal cognitive assessment (MoCA) which is used to classify non-demented PD (PD dementia is 10/15)
  • Clinical diagnosis of dementia or other severe cognitive impairment (PD = MoCA <21/30, Controls = MoCA <26/30)
  • History of stroke, traumatic brain injury or other neurological disorders (other than PD, for that group)
  • Acute lower back or lower extremity pain, peripheral neuropathy, rheumatic and orthopaedic diseases
  • Unstable medical condition including cardio-vascular instability in the past 6 months
  • Unable to comply with the testing protocol or currently participating in another interfering research project
  • Interfering therapy

Vision specific Criteria

  • Any pupillary diameter disorder; such as significantly non-round pupils, Adies pupil (tonic or dilated pupil), Argyll-Robertson pupil (absence of light reaction), unilateral small pupil
  • Neuromotility disorders, such as Nystagmus or other ocular oscillations
  • Significant left eye disorders (i.e. squint, twitching, Ptosis [drooping eyelids])
  • Known significant visual field deficits; such as hemianopia
  • Optic nerve disease
  • Optic disc elevation
  • Optic disc swelling; such as Papilledema or Papillitis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02610634). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search